Supporting these results, activation of the GPR120/FFAR4 receptor with agonists in a psoriasis model resulted in the attenuation of skin lesions, a decrease in inflammatory cytokine levels, and inhibition of Th17 cell differentiation [158]. Here, FFAR4 is linked to psoriasis.